Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LES
|
|||
| Former ID |
DNCL003530
|
|||
| Drug Name |
MEGF0444A
|
|||
| Indication | Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Phase 2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epidermal growth factor-like protein 7 (EGFL7) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.